← All trials
NCT01889433
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Nov 1, 2016
- Completion date
- Nov 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- BiocadLead sponsor
- LLC Medical Company Hepatolog, Samara, RussiaOverall official - principal investigator
- Regional State Healthcare Institution Smolensk Regional Clinical HospitalOverall official - principal investigator
- Kirov Military Medical AcademyOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- M V Hospital & Research Center, LucknowOverall official - principal investigator
- Moscow City Health DepartmentOverall official - principal investigator
- Suyash Hospital Pvt. LtdOverall official - principal investigator
- V.I. Razumovsky, Healthcare Committee at the Administration of Saratov City Municipal DistrictOverall official - principal investigator
- Moscow State UniversityOverall official - principal investigator
- Siriraj HospitalOverall official - principal investigator
- Medipoint Hospitals Pvt. Ltd.Overall official - principal investigator
- Bharti HospitalOverall official - principal investigator
- Chiangmai UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.